547 The Phase III trial of olpasiran aims to compare its effects with the placebo on the risk of coronary heart disease death, myocardial infarction, and urgent coronary revascularization in ASCVD patients with elevated Lp(a), with results expected by 2026 (NCT05581303)
Lifestyle factors significantly affect detox capacity: daily alcohol intake strains the liver and promotes fat accumulation
The latest data for orforglipron, a daily oral small molecule GLP-1 mimic developed by Lilly for weight management and T2D, showed around 10.5% weight loss in the ATTAIN-2 clinical trial in diabetic patients, compared to 2.2% weight loss for those on placebo
Call Rather Than Guess Contact the practice when pain is bothersome, unexpected, or associated with another symptom
Packed with a high content of 100000mg of L-carnitine per pack, our premium formula is a true powerhouse
Without adequate glutathione reserves, acetaldehyde accumulates in hepatocytes and crosses the blood-brain barrier, where it disrupts neurotransmitter synthesis and causes the cognitive symptoms of hangover